MGNet Pilot Studies Program

MGNet试点研究计划的主要目的是促进高度 创新的早期研究侧重于发现预测治疗的生物标记物， 通过增强以患者为中心的结果衡量标准来改善临床试验准备情况，或者 重症肌无力(MG)临床试验的流程改进。MGNet RDCRC将会有更多 准确定义MG亚型的临床表型(胸腺瘤相关、乙酰胆碱 晚发型和早发性受体抗体阳性，肌肉特异性激酶阳性，AchR- 麝香阴性)，再加上生物斯佩西姆收集。这些丰富的资源将可用于 试行拨款建议，让受助人受惠于临床MGNet核心服务 研究协调员培训、免疫学和生物统计学。调查人员还将积极 与MGNet管理层和调查人员合作，确保成功完成 研究里程碑。MGNet将每年申请一次，只选择最多的 实现MGNet目标的有希望的建议。试点研究计划从以下方面受益匪浅 MG美国基金会和Conquer MG的合作，这两家公司已同意参与 他们现有的试点赠款计划纳入了MGNet RDCRC。

The primary purpose of the MGNet pilot study program is to promote development of highly innovative early stage investigations focused on discovery of biomarkers predictive of treatment, improve clinical trial readiness through enhancement of patient-centered outcome measures, or process improvement of clinical trials in myasthenia gravis (MG). The MGNet RDCRC will more precisely define the clinical phenotype of MG subtypes (thymoma-associated, acetylcholine receptor antibody-positive of late- and early-onset, muscle-specific kinase-positive, ACHR- MUSK negative) coupled with biospecimen collection. This rich resource will be available for pilot grant proposals with grant recipients benefiting from MGNet core services in clinical research coordinator training, immunology, and biostatistics. Investigators will also actively collaborate with MGNet administration and investigators to assure successful completion of study milestones. MGNet will request applications on an annual basis and only select the most promising proposals that fulfill MGNet goals. The pilot study program benefits greatly from the collaboration of the MG Foundation of America and Conquer MG, which have agreed to fold in their existing pilot grant programs into the MGNet RDCRC.